<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00210392</url>
  </required_header>
  <id_info>
    <org_study_id>IELSG25B</org_study_id>
    <nct_id>NCT00210392</nct_id>
  </id_info>
  <brief_title>VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy</brief_title>
  <official_title>Phase II Study of VELCADE in Patients With Extranodal Marginal Zone B-Cell Lymphoma of MALT-Type Pretreated With More Than One Prior Systemic Therapy Regimen (X05142)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Extranodal Lymphoma Study Group (IELSG)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Extranodal Lymphoma Study Group (IELSG)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the antitumor activity (in terms of overall&#xD;
      response rate - ORR - i.e. sum of complete and partial responses) of bortezomib in pretreated&#xD;
      MALT lymphomas with more than one prior systemic therapy regimen&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    After IELSG25A study amendment, patients subject of the present study were eligible for&#xD;
    inclusion in the IELSG25A study&#xD;
  </why_stopped>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antitumor activity, in terms of overall response rate (ORR) i.e. sum of complete and partial responses</measure>
    <time_frame>During treatment and one month after treatment completion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety, as acute and long-term toxicity</measure>
    <time_frame>18 months after treatment completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response duration (RD) (time to relapse or progression) in responders</measure>
    <time_frame>18 months after treatment completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) (time to disease progression or death from lymphoma) in all patients</measure>
    <time_frame>18 months after study completion</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">12</enrollment>
  <condition>Lymphoma, Mucosa-Associated Lymphoid Tissue</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib (drug)</intervention_name>
    <description>Bortezomib 1,3 mg/m2 iv d1,4,8,11 every 21 days. Total 6 cycles</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. histologically proven diagnosis of marginal zone B-cell lymphoma of MALT type arisen&#xD;
             at any extranodal site&#xD;
&#xD;
          2. any stage (Ann Arbor I-IV)&#xD;
&#xD;
          3. relapsed or refractory disease pretreated with &gt; 1 prior chemotherapy regimen and/or&#xD;
             anti-CD20 immunotherapy&#xD;
&#xD;
          4. no evidence of histologic transformation to a high grade lymphoma&#xD;
&#xD;
          5. measurable or evaluable disease&#xD;
&#xD;
          6. age &gt; 18 years&#xD;
&#xD;
          7. full recovery from previous therapy, with life expectancy of at least 6 months&#xD;
&#xD;
          8. ECOG performance status 0-2&#xD;
&#xD;
          9. for primary gastric localized H. pylori-positive disease at diagnosis:&#xD;
&#xD;
               1. persistent disease 1 year after documented H. pylori infection eradication&#xD;
&#xD;
               2. clinical, endoscopic (or histologic) evidence of progression at any time after H.&#xD;
                  pylori infection eradication&#xD;
&#xD;
         10. no prior chemotherapy, immunotherapy or radiotherapy in the last 6 weeks&#xD;
&#xD;
         11. no corticosteroids during the last 4 weeks, unless prednisone chronically administered&#xD;
             at a dose &lt;20 mg/day for indications other than lymphoma or lymphoma-related symptoms&#xD;
&#xD;
         12. adequate renal function (calculated or measured creatinine clearance &gt;30 mL/minute),&#xD;
             liver function (ASAT/ALAT &lt;2,5 upper normal, total bilirubin &lt;2,5x upper normal) and&#xD;
             bone marrow function&#xD;
&#xD;
         13. no evidence of active opportunistic infections&#xD;
&#xD;
         14. no known HIV infection&#xD;
&#xD;
         15. no active HBV and/or HCV infection&#xD;
&#xD;
         16. no serious medical illness likely to interfere with participation in this clinical&#xD;
             study&#xD;
&#xD;
         17. voluntary written informed consent before performance of any study-related procedure&#xD;
&#xD;
         18. female subject is either post-menopausal or surgically sterilized or willing to use an&#xD;
             acceptable method of birth control (ie, a hormonal contraceptive, intra-uterine&#xD;
             device, diaphragm with spermicide, condom with spermicide, or abstinence) for the&#xD;
             duration of the study. Male subject agrees to use an acceptable method for&#xD;
             contraception for the duration of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. prior diagnosis of neoplasm within 5 years, except cervical intraepithelial neoplasia&#xD;
             type 1. (CIN1) or localized non-melanomatous skin cancer&#xD;
&#xD;
          2. other investigational drugs with 14 days before enrollment&#xD;
&#xD;
          3. evidence of symptomatic central nervous system (CNS) disease&#xD;
&#xD;
          4. severe impairment of bone marrow function (ANC &lt;1.0x109/L, PLT &lt;30x109/L within 14&#xD;
             days before enrollment), unless due to lymphoma involvement&#xD;
&#xD;
          5. evidence of â‰¥ grade 2 peripheral neuropathy within 14 days before enrollment&#xD;
&#xD;
          6. known hypersensitivity to bortezomib, boron or mannitol&#xD;
&#xD;
          7. pregnant or lactating status, confirmation that the subject is not pregnant must be&#xD;
             established by a negative serum beta-human chorionic gonadotropin (beta-hCG) pregnancy&#xD;
             test result obtained during screening. Pregnancy testing is not required for&#xD;
             post-menopausal or surgically sterilized women&#xD;
&#xD;
          8. any psychological, familial, sociological or geographical condition potentially&#xD;
             hampering compliance with the study protocol and follow-up schedule; those conditions&#xD;
             should be discussed with the patient before registration in the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franco Cavalli</last_name>
    <role>Study Chair</role>
    <affiliation>International Extranodal Lymphoma Study Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oncology Institute of Southern Switzerland (IOSI)</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.ielsg.org</url>
    <description>Click here for more information about this study</description>
  </link>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>March 27, 2015</last_update_submitted>
  <last_update_submitted_qc>March 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2015</last_update_posted>
  <responsible_party>
    <name_title>International Extranodal Lymphoma Study Group (IELSG)</name_title>
    <organization>IELSG</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

